AGP Picks
View all

Health Channel of Togo: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Channel of Togo.

Press releases published on July 7, 2026

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
Presentation of New Clinical Data on Givinostat  in Duchenne Muscular Dystrophy at ICNMD 2026
ENT & Allergy Associates of Pennsylvania  Expands Clinical Services with the Addition of Otolaryngologist Paul C. Frake, MD
Levicept Appoints Darlene Deptula-Hicks as CFO
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Rapid Nutrition Showcases HealthTech Strategy on Bloomberg Television

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Channel of Togo

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.